Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity. As its high-margin compounded GLP-1 business evolves, Hims & Hers ...
Durham, North Carolina, October 20th, 2025, FinanceWireMicropep Technologies, an agtech company specializing in peptide-based… Durham, North Carolina, October 20th, 2025, FinanceWire Micropep Te...
